Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C9 and VKORC1 genetic polymorphism analysis might be necessary in patients with Factor V Leiden and prothrombin gene G2021A mutation(s).

Diagnostic molecular pathology : the American journal of surgical pathology, part B - 1 Sept 2007

Leung Allen, Huang Chih-Kang, Muto Riho, Liu Yinxian, Pan Qiulu

Abstract excerpt

The annual incidence of venous thromboembolism is approximately 117 per 100,000 persons or about 1 per 1000 person-years, with the majority of the disease occurring in the older age groups. Factor V Leiden gene (most common) and the prothrombin G20210A gene mutation are inherited mild to moderate risk factors for hypercoagulability. The anticoagulant warfarin requires close monitoring of the patient's prothrombin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Blood Coagulation Disorders, Inherited

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Factor V

Share to Mixed Function Oxygenases

Share to Prothrombin

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 17721328
DOI: 10.1097/PDM.0b013e3180467811

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C9 and VKORC1 genetic polymorphism analysis might be necessary in patients with Factor V Leiden and prothrombin gene G2021A mutation(s).PMID 17721328Read ↗

Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.Semantic proximity Read ↗

The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population.Semantic proximity Read ↗

VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.Semantic proximity Read ↗

Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.Semantic proximity Read ↗

Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants.Semantic proximity Read ↗

The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.Semantic proximity Read ↗

Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.Semantic proximity Read ↗

VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy.Semantic proximity Read ↗

Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.Semantic proximity Read ↗

Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients.Semantic proximity Read ↗

Pharmacogenetics of Oral Anticoagulant TherapySemantic proximity Read ↗

Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.